230 per cent returns: This multibagger pharmaceutical company announced approval for a new drug from US FDA; do you own it? 230 per cent returns: This multibagger pharmaceutical company announced approval for a new drug from US FDA; do you own it? The company has delivered returns of 14.5 per cent over the past 3 years and returns of 230 per cent over the past 5 years. Siddharth Mane / Friday, July 14, 2023 / Article rating: 4.1 The company has a ROCE of 19.4 per cent and a ROE of 19.1 per cent.
This innovative Pharma company launches Thiamine Hydrochloride Injection USP in the United States! This innovative Pharma company launches Thiamine Hydrochloride Injection USP in the United States! The company holds a leadership position in cardiovascular, anti-diabetic and respiratory segments and is the third-largest pharmaceutical company in the U.S. by prescriptions. Siddharth Mane / Monday, June 19, 2023 / Article rating: 4.0 A global pharmaceutical company, has announced the launch of Thiamine Hydrochloride Injection USP, following the approval of its alliance partner Caplin Steriles Limited's ANDA by the U.S. FDA.
Biggest IPO of 2023 gets listed; stock surges 31.86 per cent from issue price Biggest IPO of 2023 gets listed; stock surges 31.86 per cent from issue price IPO listed with a 20.37 per cent premium on the BSE! Kamal Mansuriya / Tuesday, May 9, 2023 / Article rating: 4.5 IPO listed with a 20.37 per cent premium on the BSE!
Upper Circuit: This micro-cap pharma stock reported stellar Q3FY23 results! Upper Circuit: This micro-cap pharma stock reported stellar Q3FY23 results! In an aim to expand their product portfolio, the company is focusing on developing multiple manufacturing sites Bhavya Rathod / Monday, January 30, 2023 / Article rating: 3.7 They initiated contract manufacturing from three new locations this quarter and with this, they are currently manufacturing at nine locations across India
Only buyers: Shares of this pharmaceutical company are locked at 20 per cent upper circuit. Do you own it? Only buyers: Shares of this pharmaceutical company are locked at 20 per cent upper circuit. Do you own it? This stock is currently available at a PE multiple of 21.47 and an ROE of 9.68, all of which indicate good management effectiveness. Kiran Shroff / Tuesday, November 15, 2022 / Article rating: 4.3 This stock is currently available at a PE multiple of 21.47 and an ROE of 9.68, all of which indicate good management effectiveness.
Shilpa Medicare skyrockets by 10.47 per cent on a weak market day! Shilpa Medicare skyrockets by 10.47 per cent on a weak market day! The board of the company also has recommended a dividend of Rs 1.10 per equity share for the financial year ended March 31, 2022. Sayali Kotwal / Tuesday, May 24, 2022 / Article rating: 5.0 The shares of Shilpa Medicare soared 10.47 per cent to Rs 453.25 on BSE after the company announced promising results for the quarter that ended on March 31, 2022.